Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis
- PMID: 8229681
- DOI: 10.1007/BF01059771
Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis
Abstract
A prospective simulation study has been carried out to evaluate the effect of potential misspecification of the absorption rate constant (ka) in population pharmacokinetic analysis when few to no concentration-time data were available in the absorption phase and estimation of ka was not possible. Data were simulated for 100 subjects using a one-compartment model at steady state with first-order input. Data were generated over a range of ka values: ka was misspecified in the NONMEM analysis by factors of 0.25, 0.5, 1, 2, 3, and 4. In general, clearance (CL) was typically estimated with a small, constant underprediction, regardless of the range of misspecification of ka or whether data were present in the absorption phase. The same was not true for volume of distribution (V), values were biased and sensitive to the degree of misspecification, but only when the data contained even a little information about absorption. If studies are to be designed in which information absorption is either not required or is of no therapeutic use, then blood samples could be concentrated in the postabsorption phase and the absorption input fixed according to the best a priori information available.
Similar articles
-
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003. Clin Pharmacokinet. 2006. PMID: 16584284
-
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.Clin Pharmacokinet. 2007;46(2):159-73. doi: 10.2165/00003088-200746020-00004. Clin Pharmacokinet. 2007. PMID: 17253886
-
The influence of assay variability on pharmacokinetic parameter estimation.J Pharmacokinet Biopharm. 1989 Oct;17(5):571-92. doi: 10.1007/BF01071350. J Pharmacokinet Biopharm. 1989. PMID: 2614686
-
Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers.Biol Pharm Bull. 2006 Dec;29(12):2460-4. doi: 10.1248/bpb.29.2460. Biol Pharm Bull. 2006. PMID: 17142982
-
Effects of bladder resorption on pharmacokinetic data analysis.J Pharmacokinet Biopharm. 1994 Jun;22(3):183-205. doi: 10.1007/BF02353328. J Pharmacokinet Biopharm. 1994. PMID: 7884649 Review.
Cited by
-
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Antimicrob Agents Chemother. 2010 Dec;54(12):5242-50. doi: 10.1128/AAC.00781-10. Epub 2010 Oct 4. Antimicrob Agents Chemother. 2010. PMID: 20921307 Free PMC article. Clinical Trial.
-
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.PLoS One. 2014 Jan 31;9(1):e86919. doi: 10.1371/journal.pone.0086919. eCollection 2014. PLoS One. 2014. PMID: 24497997 Free PMC article.
-
Comparison of some practical sampling strategies for population pharmacokinetic studies.J Pharmacokinet Biopharm. 1996 Apr;24(2):245-63. doi: 10.1007/BF02353491. J Pharmacokinet Biopharm. 1996. PMID: 8875349
-
Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria.Br J Clin Pharmacol. 1998 Apr;45(4):347-54. doi: 10.1046/j.1365-2125.1998.t01-1-00686.x. Br J Clin Pharmacol. 1998. PMID: 9578181 Free PMC article.
-
Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab.Front Pharmacol. 2025 Aug 19;16:1631034. doi: 10.3389/fphar.2025.1631034. eCollection 2025. Front Pharmacol. 2025. PMID: 40904558 Free PMC article.